Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 18/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13118711 | 1.00 | CETP (0.42) | CETPCYP3A4TACR1 | |
| SCHEMBL680609 | 1.00 | CETP (0.42) | CETPCYP3A4TACR1 | |
| Hydrochloric Acid SCHEMBL680533 | 0.99 | CETP (0.41) | CETPCYP3A4TACR1 | |
| Hydrochloric Acid SCHEMBL680534 | 0.99 | CETP (0.41) | CETPCYP3A4TACR1 | |
| SCHEMBL680809 | 0.98 | CETP (0.42) | CETP | |
| SCHEMBL680808 | 0.98 | CETP (0.42) | CETP | |
| Hydrochloric Acid SCHEMBL680398 | 0.97 | CETP (0.42) | CETP | |
| Hydrochloric Acid SCHEMBL680399 | 0.97 | CETP (0.42) | CETP | |
| SCHEMBL680981 | 0.96 | CETP (0.40) | CETPCYP3A4TACR1 | |
| SCHEMBL680982 | 0.96 | CETP (0.40) | CETPCYP3A4TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828438-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase | BEND RESEARCH, INC. (US) | 2014-09-09 | — | — | US | claimed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | claimed |
| US-20090118328-A1 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase | BEND RESEARCH, INC. (US) | 2009-05-07 | — | — | US | claimed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | claimed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | claimed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | claimed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | claimed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-9867811-B2 | Method of treating atherosclerosis in high triglyceride subjects | NOVARTIS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| EP-1844078-B1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | BEND RES INC (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2006079921-A2 | DRYING OF DRUG-CONTAINING PARTICLES | PFIZER PRODUCTS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | PFIZER INC | 2006-03-23 | — | — | US | disclosed |
| WO-2005115330-A2 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | CETP 1/4885CYP3A4 448/4885TACR1 1017/4885 |
| US-20090118328-A1 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase | CETP, HMGCR, MTTP | CETP 1/4885CYP3A4 111/4885TACR1 3226/4885 |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | CETP 1/4885CYP3A4 356/4885TACR1 803/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885CYP3A4 1980/4885TACR1 1329/4885 |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | APOB, LDLR, CETP | CETP 3/4885CYP3A4 397/4885TACR1 4584/4885 |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | CETP 1/4885CYP3A4 1911/4885TACR1 1034/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885CYP3A4 584/4885TACR1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.